Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 17, 2012 Brian Orelli	Pharma Focus Is Good For Your Portfolio Build your own portfolio.
The Motley Fool March 14, 2011 Brian Orelli	This Deal Is No Dog Eli Lilly picks up Johnson & Johnson's European animal-health business.
The Motley Fool September 29, 2011 Brian Orelli	Joint-Venture Acid Reflux Merck ditches its joint venture with Johnson & Johnson.
The Motley Fool September 15, 2011 Brian Orelli	Stop Worrying About Pfizer's Breakup Sometimes you just have to trust management.
The Motley Fool January 28, 2009 Brian Orelli	A Mini-Pfizer in the Making Bristol-Myers Squibb looks like its setting itself up to be the next Pfizer.
The Motley Fool March 24, 2009 Robert Steyer	Drugmakers Diversify -- Again Merck and Pfizer choose businesses they once eschewed.
The Motley Fool November 30, 2011 Brian Orelli	3 Things More Important to Pfizer Than Losing Lipitor It's not like we didn't see it coming.
The Motley Fool March 30, 2011 Brian Orelli	How to Play the Pfizer Breakup (If It Happens) The sum of the parts could be worth more than the whole.
The Motley Fool March 22, 2011 Brian Orelli	Pharmas in the Doghouse Merck and Sanofi call off their joint venture.
The Motley Fool November 17, 2009 Brian Orelli	Up 80%, It's Time to Sell Bristol-Myers to Mead Johnson: It's time to walk on your own. Investors will have an option of exchanging some or all of their Bristol-Myers shares for shares in Mead Johnson for a slight discount
The Motley Fool August 3, 2011 Brian Orelli	Ignore Pfizer's Financials for Now It's the pipeline that matters.
The Motley Fool September 22, 2009 Brian Orelli	Pfizer and Wyeth Put the Horse Before the Cart The pharmas' animal-business divestiture brings them one step closer to unity.
The Motley Fool March 8, 2010 Brian Orelli	Pfizer Still Dealing With Antitrust Issues The pharma giant sells off some more animal health assets.
The Motley Fool December 18, 2008 Brian Orelli	Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009.
The Motley Fool February 19, 2009 Robert Steyer	IPO Food for Thought The bosses at Pfizer should be interested in the recent Mead Johnson IPO so as to place a value on Wyeth's nutrition business.
The Motley Fool December 30, 2010 Brian Orelli	Pfizer Diagnoses Fido, Too The drugmaker's animal health division purchases Synbiotics.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool October 30, 2009 Brian Orelli	World's Scariest Stocks: Pfizer For Pfizer, the big, scary unknown comes from whether it can integrate its recent acquisition of Wyeth.
The Motley Fool December 22, 2009 Brian Orelli	This Acquisition Is Icy Hot Expensive price, but Chattem may still be a good buy for sanofi-aventis.
The Motley Fool July 9, 2010 Brian Orelli	Hey, Johnson & Johnson: Eight Is Enough If Johnson & Johnson can't overcome the negative image from recalls quickly, consumers will head to competing brand-name drugs or just grab generic versions of Johnson & Johnson's products.
The Motley Fool September 1, 2009 Brian Orelli	Merck to Bride: Leave the Jewelry at Home The new Merck will look a lot like the old Merck at the top, even though about 40% of Schering's senior leaders will be headed to the new company.
The Motley Fool January 28, 2010 Brian Orelli	Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds.
The Motley Fool January 29, 2010 Brian Orelli	All Grown Up, With Cash to Burn Bristol-Myers is all drugs, all the time.
The Motley Fool October 19, 2011 Brian Orelli	Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson.
The Motley Fool February 3, 2010 Brian Orelli	Wyeth Can't Save Pfizer Not much earnings growth, but the price is right.
The Motley Fool May 12, 2009 Brian Orelli	Another Reason to Hate Big Pharma's M&A As we get closer to Pfizer and Merck wrapping up their deals, it looks like a new group is voicing their displeasure: external partners.
The Motley Fool December 17, 2009 Brian Orelli	This Acquisition Hears, Smells, and Tastes Soooo Good Johnson & Johnson picks up an ear, nose, and throat medical device maker.
The Motley Fool November 30, 2009 Brian Orelli	Making Money More Efficiently Drug companies shape up, and it shows in their margins.
The Motley Fool August 12, 2011 David Williamson	What Happened to U.S. Pharma? How did the domestic pharmaceutical industry fare in the most recent quarter?
The Motley Fool February 29, 2008 Brian Orelli	2007 Pharma Roundup How did big pharma do in 2007? With the drug sector earnings season winding down, now seems like a good time to take a look at how they fared and, more importantly, where they're headed.
The Motley Fool January 15, 2009 Robert Steyer	For Pfizer, a Big Buy Could Be a Big Mistake Pfizer's CEO says the company must make a big, bold buy to reverse course on its skidding stock and to blast it out of its revenue doldrums. Is it the right move?
The Motley Fool January 23, 2007 Ryan Fuhrmann	Pfizer Pfizzles Through 2006 The company is in a top-line pickle, but it expects things to get better. Current investors are now left standing until a rebound in growth, now targeted for 2009.
The Motley Fool July 21, 2009 Brian Orelli	Foolish Forecast: Pfizer Meanders Toward Merger Let's look at what to expect when the pharmaceutical giant releases earnings tomorrow.
The Motley Fool November 13, 2007 Brian Orelli	Another Punch in the Nose for Pfizer The FDA clears ZYRTEC-D for over-the-counter sales; marketing of the medication will now switch hands from Pfizer to Johnson & Johnson. Investors, take note.
The Motley Fool July 2, 2009 Brian Orelli	Squeezing Blood From a Half-Dollar Johnson & Johnson is investing $1 billion in Elan in exchange for an 18.4% stake in the company.
The Motley Fool January 12, 2012 Brian Orelli	What to Look For From Pfizer in 2012 Leaner? Yes. Meaner? We'll see.
The Motley Fool February 25, 2010 Brian Orelli	13 Is Pfizer's Lucky Number Inherited from Wyeth, Prevnar 13 could be a goldmine for Pfizer.
The Motley Fool December 9, 2009 Brian Orelli	Welcome to Club Biogeneric, Pfizer! The megadrugmaker jumps on the biogeneric bandwagon.
The Motley Fool May 4, 2011 Brian Orelli	For Pfizer, Breaking Up Is Hard to Do CEO Ian Read pushes back the decision on the company's breakup until 2012.
The Motley Fool November 26, 2010 Brian Orelli	Get It Together, Johnson & Johnson Another day, another recall.
The Motley Fool August 19, 2010 Brian Orelli	Buffett Is Buying J&J. Should You? It depends on your time horizon.
The Motley Fool July 31, 2007 Nathan Parmelee	Break Out the Band-Aids at J&J Johnson & Johnson is making some deep cuts to change its cost structure. Shareholders haven't had much to cheer about lately here, but the potential benefits from this move could help cure some of the current softness in the business.
The Motley Fool July 19, 2011 Brian Orelli	J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile.
The Motley Fool June 23, 2010 Brian Orelli	Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise.
The Motley Fool September 17, 2008 Brian Orelli	IPO? In This Market? Bristol-Myers continues with plans to spin off its nutritionals business.
The Motley Fool October 27, 2009 Brian Orelli	Pfizer's and Merck's Loss Is These Companies' Gain Are Pfizer and Merck too busy integrating now to take advantage of additional acquisitions?
The Motley Fool October 19, 2009 Brian Orelli	Foolish Forecast: A Last Look at "Mini" Pfizer In advance of Pfizer's last earnings report before their acquisition of Wyeth, analysts expect a drop in sales and a bigger bottom line decrease.
The Motley Fool June 15, 2010 Brian Orelli	Pfizer Focuses, Investors Should Cheer The culling of the pipeline continues at Pfizer. While that's bad news for partners that signed on with the company or with Wyeth before the merger it's a good move for Pfizer.
The Motley Fool March 23, 2009 Brian Orelli	Which Pharmas Still Have Cash? Pharmaceutical mergers-and-acquisitions activity has been jumping for the past few months, but the consolidation can't go on forever.
The Motley Fool August 24, 2010 Brian Orelli	One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well.